🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Se non sei a #ESMO2024 non puoi perderti #ESMOCafè. Un modo rilassato di rimanere aggiornato sui più importanti dati in area GU con il parere degli esperti. Oggi Elena Verzoni Pasquale Rescigno. Prepara un caffe ☕️ e collegati alle 8.00!

Great session!@AIOMtweet

Cabozantinib plus Durvalumab is active and safe in platinum chemotx pregressing mUC and Variant Histologies patients. Data presented at #AIOM2024 AIOM Patrizia Giannatempo Giuseppe Procopio Andrea Necchi @valentinaguadalupi Roberto Iacovelli Daniele Raggi Alessandro Rametta

Meet-URO Academy Seconda Edizione Iniziati oggi i lavori della Meet-URO Academy Milano, in questo modulo: come leggere e interpretare un lavoro scientifico, come scrivere un articolo scientifico, comunicazione medico paziente. Buon lavoro! Giuseppe Procopio

A prospective real-world study of cabozantinib in patients with advanced renal cell carcinoma (CASSIOPE)   doi.org/10.1016/j.clgc… Istituto Tumori Elena Verzoni OncoAlert Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Petros Grivas Kidney Cancer Tumori Journal ANTURE - Associazione Nazionale Tumore del Rene

As years go by, Cabozantinib remain SoC for pretreated mRCC patients Enjoy our last 2024 achievement (CASSIOPE trial) on Clinical Genitourinary Cancer clinical-genitourinary-cancer.com/article/S1558-… Giuseppe Procopio Elena Verzoni Michael Staehler BARTHELEMY PHILIPPE

Ready for tomorrow! “Controversies in GenitourinaryTumors’’, a dynamic event exploring the latest debates in GU Oncology. Top experts, innovative discussions, and cutting-edge insights await. 🗓 30 January 2025📍 Istituto Tumori, Milano

30/1 all'Istituto Tumori congresso internazionale "Controversies in Genitourinary Tumors". Scopri le ultime novità di aggiornamento sulle innovazioni che stanno trasformando la lotta contro i tumori genitourinari. #IstitutoTumoriMilano #TumoriGenitourinari rb.gy/tl1x0s

Let’s start with prostate cancer session! #controversiesinGu#@IstitutoTumri@g_procopio_ HÜSEYİN Istituto Tumori

Great session on renal cell treatment challenges! Giuseppe Procopio Daniel Heng

1/7 Pleased to share updated OS results from the #TIVO-3 study (NCT02627963), previously presented at #ESMO24. Our analysis focused on outcomes in patients with #ccRCC who had received prior treatment with a checkpoint inhibitor (CPI) - representing 26% of the trial population.

We’re excited to announce that Meet-URO will be presenting the following poster at the upcoming #ASCOGU2025 in San Francisco. Don’t miss the chance to explore new insight in #RCC Elena Verzoni Meet-URO Davide Bimbatti

Our poster has been selected for tomorrow’s poster walks 🤩Come to see it and enjoy the walk! #GU25 #collectingductcarcinoma

🔵 Grazie a tutti i partecipanti della #MeetUroAcademy 2025! Si è concluso il primo di tre moduli dell'anno, dedicato a oncogeriatria e intelligenza artificiale in uro-oncologia. Il percorso continua! Ci vediamo ai prossimi appuntamenti, 08-09 maggio e 20-21 novembre!

Have you ever heard about pathologic Complete Response in RCC? Enjoy our case series of patients treated with Cabozantinib Nivolumab #RCC #cabozantinib #nivolumab #CancerResearch #meeturo Giuseppe Procopio Elena Verzoni Simone rota Istituto Tumori

VHIO hosted a face-to-face meeting as part of the Women in #RCC Kidney Cancer mentoring program ‼️ Cristina Suárez, Lisa Pickering, Laurence Albiges, Manuela Schmidinger & Elena Verzoni came together to support junior women oncologists in the field of kidney cancer. The program now moves

Today is #WorldKidneyCancerDay! To mark the occasion, Istituto Tumori is hosting a special event for patients about genitourinary cancers: a space for support, information, and connection. #KidneyCancer #GUcancer #Oncology #PatientSupport

Excited to share our work performed at National Cancer Institute addressing needs of rare hereditary kidney cancer through bench to bedside work Bevacizumab + erlotinib for #HLRCC assoc RCC 📍Response rate 72% 📍mPFS 21.1 mo Thanks to the patients who supported the study! nejm.org/doi/full/10.10…

🌟 #MeetTheEditors Genitourinary Oncology Section of TJ, led by dr. Giuseppe Giuseppe Procopio , dr. Patrizia Patrizia Giannatempo and dr. Marcello Tucci, is focused on evaluation of articles on detection, diagnosis, prevention and treatment of genitourinary tumors, promoting studies